These findings collectively support the conclusion that genetic predisposition, particularly the ABCG2 c.421C>A variant, is a critical determinant of treatment persistence, potentially through its role exacerbating adverse effects like SAMS. Here, ABCG2 is linked to short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome.